Search research articles
Contact Us
Filters
Showing results (161-170 of 212) with videos related to
Page
of 22
Sort By:
Blood
|
October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Nicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
British Journal of Haematology
|
December 21, 2022
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia
Enrico Tiacci, Alessandro Mancini, Monia Marchetti, et al.
Cancer Genetics and Cytogenetics
|
May 18, 2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications
Alfonso Zaccaria, Nicoletta Testoni, Anna Maria Valenti, et al.
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Blood
|
June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
Simona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Blood
|
December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
Mattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
British Journal of Haematology
|
September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study
Artur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
British Journal of Haematology
|
March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.
Frontiers in Oncology
|
December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
Andrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Blood Neoplasia
|
January 2, 2026
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response
Anna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 212) with videos related to
Sort By:
Page
of 22
Blood
|
October 3, 2009
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
Nicoletta Testoni, Giulia Marzocchi, Simona Luatti, et al.
British Journal of Haematology
|
December 21, 2022
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia
Enrico Tiacci, Alessandro Mancini, Monia Marchetti, et al.
Cancer Genetics and Cytogenetics
|
May 18, 2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications
Alfonso Zaccaria, Nicoletta Testoni, Anna Maria Valenti, et al.
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Blood
|
June 14, 2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
Simona Luatti, Fausto Castagnetti, Giulia Marzocchi, et al.
Blood
|
December 4, 2023
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
Mattia D'Agostino, Giuseppe Bertuglia, Delia Rota-Scalabrini, et al.
British Journal of Haematology
|
September 30, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study
Artur Jurczyszyn, Hareth Nahi, Irit Avivi, et al.
British Journal of Haematology
|
March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.
Frontiers in Oncology
|
December 8, 2022
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
Andrea Visentin, Francesca Romana Mauro, Gioachino Catania, et al.
Blood Neoplasia
|
January 2, 2026
Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response
Anna Maria Corsale, Mojtaba Shekarkar Azgomi, Emilia Gigliotta, et al.
Page
of 22